Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Type/Product Area | Terms/Details (Date) |
| | |||
Access Pharmaceuticals Inc. (AMEX:AKC) |
Unnamed pharmaceutical company |
Collaboration on oral drug-delivery formulations |
Access's vitamin B12 delivery technology will be used with the partner's formulations; terms were not disclosed (5/13) |
Active Biotech AB (Sweden; SSE:ACTI) |
Teva Pharmaceuticals Inc. (Israel) |
Collaboration on Active Biotech's immunomodulatory compound laquinimod, which has completed Phase II trials in multiple sclerosis |
Teva got exclusive rights outside the Nordic and Baltic countries; Teva will pay $5M up front, cover development expenses and pay up to $87M in milestones, as well as double-digit royalties on any sales (6/14) |
Advancis Pharmaceutical Corp. (AVNC) |
Par Pharmaceutical Inc. |
Companies entered a definitive agreement to develop Advancis' Amoxicillin Pulsys |
Par is paying $5M up front and will fund further development in exchange for exclusive sales rights and coexclusive rights to market the pulsatile bactericidal; they would split profits equally (6/2) |
Althea Technologies Inc.* |
Beckman Coulter Inc. |
Beckman exclusively licensed Althea's eXpress Profiling technology |
The technology will be integrated into the GenomeLab suite of genetic analysis solutions; terms were not disclosed (6/3) |
AplaGen GmbH* (Germany) |
Lonza Group Ltd. (Switzerland) |
Collaboration and license agreement for AplaGen's CFPS technology |
The technology is for synthesis of peptides and proteins; terms of the deal were not disclosed (5/11) |
BioBase GmbH* (Germany) |
BASF Plant Science GmbH (Germany) |
BASF licensed the Brenda enzyme database |
BASF will use the data in its chemistry division and in plant biotechnology; terms were not disclosed (6/1) |
Bionomics Ltd. (Australia; ASX:BNO) |
PerkinElmer Inc. |
Collaboration to evaluate and optimize new ion channel reagents for CNS diseases using Bionomics' ionX program |
Bionomics also will incorporate Perkin-Elmer's ImageTrak platform into its CNS discovery programs, and will serve as a reference site for PerkinElmer's cellular-screening platforms in Asia (5/10) |
Cell Signaling Technology Inc.* |
AstraZeneca plc (UK) |
CST will study AstraZeneca compounds to discover biomarkers of protein tyrosine kinase target inhibition |
CST will use its Global Phospho- signature technology in the deal, terms of which were not disclosed (6/7) |
Celltech Group plc (UK; NYSE:CLL) |
UCB SA (Belgium) |
UCB gained co-exclusive worldwide rights to CDP870, an anti-TNF-alpha antibody fragment |
UCB, which also plans to acquire Celltech, will pay development expenses and would make milestone and royalty payments; its exclusive rights do not include Crohn's disease (5/18) |
Concurrent Pharmaceuticals Inc.* |
Allergan Inc. |
Concurrent acquired research and preclinical programs in retinoid and rexinoid nuclear receptors |
Allergan gets an equity stake in Concurrent, as well as potential milestones and royalties; the products have application in diabetes, cancer and dermatology (5/26) |
CyDex Inc.* |
Hovione (Portugal) |
Deal to use CyDex's Captisol technology to develop new formulations of nonpatented drugs |
They initially plan to develop formulations of six undisclosed drugs; Hovione already manufactures the Captisol technology (6/14) |
Dragon Pharmaceutical Inc. (Canada; TSE:DDD) |
Suzhou Zhongkai Bio-Pharmaceuticals Co. Ltd. (China) |
Dragon licensed rights to Zhongkai's recombinant human granulocyte-colony stimulating factor |
Dragon's rights are exclusive worldwide except China; terms were not disclosed (4/22) |
Elite Pharmaceuticals Inc. (AMEX:ELI) |
Purdue Pharma LP |
Purdue got an exclusive right to evaluate certain abuse- resistant formulation technology |
Purdue also got an exclusive option to negotiate a license to oxycodone products under the Elite technology; terms were not disclosed (5/10) |
Evotec OAI AG (Germany; FSE:EVT) |
F. Hoffmann-La Roche Ltd.(Switzerland) |
Worldwide discovery chemistry agreement |
The companies have had three chemistry alliances since 2001; terms were not disclosed (5/12) |
First Genetic Trust Inc.* |
GlaxoSmithKline plc (UK) |
Collaboration to evaluate the relationship between genetic variations and certain adverse drug reactions |
Terms of the pharmacogenetics effort were not disclosed (5/25) |
Gene-IT Inc.* |
Aventis SA (France) |
Aventis licensed the Genome-Quest software for sequence searching |
Aventis intellectual property investigators had access to the software for validation purposes; terms were not disclosed (5/11) |
GeneProt Inc.* (Switzerland) |
H. Lunbeck A/S (Denmark) |
Collaboration to study the proteomics of biofluid samples taken from a rodent model of CNS disease |
Lundbeck has exclusive rights to commercialize results of the effort; further details were not disclosed (4/22) |
Genetronics Biomedical Corp. (AMEX:GEB) |
Merck & Co. Inc. |
Collaboration to develop Genetronics' MedPulser delivery system for use with certain Merck DNA vaccine programs |
Genetronics gets an up-front payment and potential milestones and royalties; Merck can use the technology with two antigens and has an option to add others; the deal follows an evaluation agreement entered in 2003 (5/24) |
Genfit SA* (France) |
Les Laboratoires Servier (France) |
Collaboration to identify drug candidates in the field of obesity and related metabolic disorders |
The five-year deal provides Genfit with an up-front payment, annual research funding and potential milestones and royalties; the work initially will focus on two targets (5/24) |
GenOway SA* (France) |
Altana AG (Germany) |
GenOway will generate knockout and knock-in rat models for Altana |
Terms were not disclosed (5/24) |
Genzyme Corp. (GENZ) |
Medtronic Inc. |
Formed joint venture named MG Biotherapeutics to develop treatments for cardiovascular disease |
They will use Medtronic's delivery devices and other technologies with Genzyme's biological expertise in the area; Genzyme's Phase II trial using cell therapy for repairing damaged heart tissue is part of the deal, the terms of which were not disclosed (6/1) |
Gilead Sciences Inc. (GILD) |
Bristol-Myers Squibb Co. and Merck & Co. Inc. |
Discussing a deal to create a once-daily, fixed-dose combination of three HIV drugs |
The combined product would include Gilead's Viread and Emtriva, as well as the pharma companies' efavirenz (Sustiva); terms were not disclosed (5/16) |
GTx Inc. (GTXI) |
Hybritech Inc. (unit of Beckman Coulter Inc.) |
GTx will provide Hybritech clinical samples from its Phase IIb trial of Acapodene for prostatic intraepithelial neoplasia |
Beckman Coulter will determine the data's usefulness in evaluation of assays for prostate disease; terms were not disclosed (4/22) |
HTG Inc.* |
Merck & Co. Inc. |
Merck licensed HTG's ArrayPlate qNPA technology |
Details of the deal were not disclosed (5/4) |
Iconix Pharmaceuticals Inc.* |
Taisho Pharmaceutical Co. Ltd. (Japan) |
Iconix will provide chemo- genomic profiling and analytical services for a Taisho discovery compound |
Iconix's DrugMatrix platform, chemogenomics technology and Drug Signature library will be used in the deal, terms of which were not disclosed (6/15) |
Iconix Pharmaceuticals Inc.* |
AstraZeneca plc (UK) |
Iconix will provide chemogenomic profiling and analytical services for an AstraZeneca cancer drug discovery program |
AstraZeneca also wants to identify genomic biomarkers that can be used as counter-screens in short- erm studies; terms were not disclosed (6/2) |
Innogenetics NV (Belgium; Euronext:INNX) |
Takeda Chemical Industries Ltd. (Japan) |
Innogenetics gains access to Takeda's patent rights for diagnostic and research uses of beta-amyloid antibodies |
The license is worldwide and will be used in Innogenetics' work in neurodegenerative biomarkers; terms were not disclosed (6/9) |
Inpharmatica Ltd.* (UK) |
Procter & Gamble Pharmaceuticals Inc. |
P&G will fund research focused on analysis of human G protein-coupled receptors |
Inpharmatica also will receive license fees for discoveries arising from the deal, which will involve its PharmaCarta platform (5/18) |
Inverness Medical Innovations Inc. (AMEX:IMA) |
Roche Diagnostics |
Inverness exercised an option for a nonexclusive license related to immunoassays that detect the NT-proBNP marker of congestive heart failure |
Inverness got the option as part of a 2003 settlement between the companies of litigation relating to Inverness's rapid assay lateral-flow patents; terms were not disclosed (4/28) |
Jerini AG* (Germany) |
Baxter Healthcare Corp. |
Expanded 2001 collaboration into alliance to develop peptidmimetic drugs against an undisclosed target |
Baxter also has an exclusive option to develop other peptidomimetics against further targets; Jerini gets undisclosed up-front and personnel funding, and potential milestones and royalties (4/29) |
Lectus Therapeutics Ltd.* (UK) |
Takeda Chemical Industries Ltd. (Japan) |
Takeda is supporting a project using Lectus' Leptics technology for ion channel drug discovery |
Takeda is paying $1.8M for research Leptus will carry out on an undisclosed target (5/6) |
MediciNova Inc.* |
Mitsubishi Pharma Corp. (Japan) |
MediciNova acquired the Phase II anxiety drug MKC-242 (now named MN-305) |
MediciNova got exclusive rights, except for an ophthalmic solution, to the 5-HT1A receptor agonist, worldwide except Japan, China and other Southeast Asian countries; terms were not disclosed (6/10) |
Merrimack Pharmaceuticals Inc.* |
Novartis Institutes for BioMedical Research Inc. |
Research collaboration under which Novartis will use the Network Biology platform from Merrimack |
Terms of the deal were not disclosed; the technology provides insight into signaling pathways (6/1) |
Micrologix Biotech Inc. (Canada; TSE:MBI) |
Unnamed company |
Micrologix entered negotiations to license MBI-226, an anti-microbial cationic peptide in Phase III trials |
Micrologix gets a fee in exchange for negotiating a definitive license agreement with the company exclusively for 60 days (6/3) |
MorphoSys AG (Germany; FSE:MOR) |
Novartis AG (Switzerland) |
Collaboration to discover and develop antibody-based drugs for a variety of diseases |
MorphoSys gets more than $30M in R&D funding and license fees over the first three years of the deal, and can get additional license payments, milestones and royalties on sales; Novartis also is buying $10.9M of MorphoSys convertible bonds (5/19) |
Nektar Therapeutics (NKTR) |
GlaxoSmithKline plc (UK) |
GSK licensed Nektar's PEGylation technology for use with a preclinical protein under development for cancer |
Nektar can get milestone payments and manufacturing revenues during development, as well as potential royalty and manufacturing revenues upon approval (5/5) |
Newron Pharmaceuticals SpA (Italy) |
Zambon Group SpA (Italy) |
Collaboration to discover and develop sodium and calcium channel blockers for treating pain conditions |
Newron would receive a milestone payment upon selection of the first candidate; the companies will jointly share all costs and would share revenues equally (5/6) |
NicOx SA (France; OTC BB:NICXF) |
Grupo Ferrer International SA (Spain) |
Deal to develop and market steroid derivatives for dermatological diseases in Europe, Latin America and French-speaking Africa |
NicOx retains co-promotion rights in Europe and all rights in the U.S. and Asia; it is entitled to milestone and royalty payments; NCX 1022 was selected as the lead compound in the collaboration (4/29) |
Ovation Pharmaceuticals Inc.* |
H. Lundbeck A/S(Denmark) |
Ovation acquired Buronil, a product for schizophrenia and other CNS disorders |
Ovation assumes all responsibilities in Europe, where the product is approved, and will assess the opportunity in the U.S.; terms were not disclosed (6/15) |
ParAllele BioScience Inc.* |
Merck & Co. Inc. |
Collaboration to discover genetic variations that may impact susceptibility, prognosis or response to therapy |
ParAllele will use its single nucleotide poly-morphism and genotyping technologies to discover and characterize variants among genes identified by Merck; terms were not disclosed (5/12) |
PowerMed Ltd. (UK; spin off from Chiron Corp.; CHIR) |
GlaxoSmithKline plc (UK) |
GSK gained additional licenses to the PowderJect powder injection technology in oncology |
As part of the deal, PowerMed acquired two former GSK DNA vaccine programs that were based on the technology; terms were not disclosed (5/17) |
Praecis Pharmaceuticals Inc. (PRCS) |
Schering AG (Germany) |
Schering will commercialize Plenaxis for prostate cancer in Europe, Russia, the Middle East, South Africa, Australia and New Zealand |
Praecis could receive up-front and milestone payments of up to $90M, as well as a share of revenue through transfer price payments; a marketing application has been filed in Germany, which if successful would be followed by a full filing in the European Union (4/28) |
Protein Design Labs Inc. (PDLI) |
Abbott Laboratories |
Abbott gained broad access to PDL's technology for antibody humanization |
PDL will humanize up to three antibodies for Abbott, and could humanize subsequent antibodies at the election of Abbott; PDL can get milestone payments and royalties on resulting products (6/7) |
RNA-TEC NV* (Belgium) |
Lonza Group Ltd. (Switzerland) |
Companies will combine efforts to provide synthesis expertise to the RNA market |
The deal focuses on TBDMS-based oligonucleotides; they are investigating other potential areas of synergy (4/26) |
RNAx GmbH* (Germany) |
Proligo LLC (Germany; unit of Degussa AG) |
Proligo will access RNAi technology for functional validation of siRNA technologies |
Proligo will own resulting products; terms were not disclosed (4/26) |
Senetek plc (SNTK) |
Valeant Pharmaceuticals International |
Valeant got the right to an exclusive worldwide license to Zeatin, a naturally occurring analogue of Kinetin |
Valeant already markets Senetek's Kinerase brand of Kinetin dermatological products; the new deal is under similar terms; Valeant also is paying Senetek $5M to expand its Kinerase rights and reduce the royalties it pays (5/10) |
Sirenade Pharmaceuticals AG* (Germany) |
Polichem SA (Switzerland) |
Deal to develop a sustained- release formulation of DHEC, a dopamine agonist with neuroprotective activity |
Sirenade will develop a new formulation of the compound, which is sold in Europe in an immediate- release formulation; terms were not disclosed (5/10) |
SkyePharma plc (UK; SKYE) |
First Horizon Pharmaceutical Corp. |
First Horizon got U.S. rights to an undisclosed cardiovascular product that's under FDA review |
SkyePharma would get $20M in milestones upon FDA approval and could get $30M in sales-related milestones; it also would get 25% of net sales; First Horizon also got the first rights to a future cardiovascular product using SkyePharma's technology (5/17) |
Spectrum Pharmaceuticals Inc. (SPPI) |
Shantha Biotechnics Pvt. Ltd. (India) |
Spectrum will be responsible for regulatory and marketing matters in the U.S. for certain Shantha products |
The products, some approved outside the U.S. and some under development, include cancer drugs and diagnostics, and vaccines; terms were not disclosed (5/14) |
Syrrx Inc. |
Hoffmann-La Roche Inc. |
Collaboration to discover and develop drugs for cancer and Type II diabetes; the focus is the HDAC target for cancer and the metabolic target 11-beta HSD-1 |
Syrrx will advance products through early development; Roche has an option to license worldwide rights; Syrrx gets an undisclosed up-front payment and milestones, and other payments of up to $178M, as well as royalties on any sales (5/12) |
Taconic Inc.* |
DuPont |
Taconic got an exclusive sub-license to produce and distribute the rasH2 mouse used for toxicology and carcinogenecity testing |
The license is worldwide except in Japan, where mouse developer the Central Institute for Experimental Animals of Japan has rights; terms were not disclosed (6/15) |
Target Discovery Inc.* |
Groton Biosystems LLC |
Collaboration to combine technologies for products with protein-production applications |
They are working on capillary electrophoresis analysis systems; terms of the deal were not disclosed (6/3) |
Tercica Inc. (TRCA) |
Fujisawa Pharmaceutical Co. Ltd. (Japan) |
Tercica got a nonexclusive license to use recombinant human insulin-like growth factor-I for treating forms of extreme insulin resistance |
Tercica has nonexclusive rights worldwide except in Japan; terms were not disclosed (4/29) |
TransForm Pharmaceuticals Inc.* |
Abbott Laboratories |
TransForm will perform crystallization and formulation studies on Abbott compounds |
They will work to enhance attributes of the selected compounds; terms were not disclosed (6/3) |
Tripos Inc. (TRPS) |
Bayer HealthCare AG (Germany) |
Bayer will deploy Tripos' discovery informatics software across its organization |
Bayer gained rights to use the Sybyl and Unity software under undisclosed terms (5/26) |
Vertex Pharmaceuticals Inc. (VRTX) |
Mitsubishi Pharma Corp. (Japan) |
Collaboration on Vertex's VX-950, an oral protease inhibitor in Phase I for treating hepatitis C virus infection |
Mitsubishi gained rights in Japan and Far Eastern countries in exchange for development support, license fees and milestones that together could total $33M, as well as royalties on any sales (6/14) |
Wilex AG* (Germany) |
Laboratorios de Dr. Esteve SA (Spain) |
Co-development and marketing deal for Wilex's chimeric antibody Rencarex in Spain, Italy, Portugal, Greece and Andorra |
Esteve gets exclusive rights in those areas in exchange for an undisclosed up-front payment, milestone payments and royalties on sales; Esteve also will co-sponsor in Spain the upcoming Phase III trial of Rencarex in renal-cell carcinoma (4/26) |
Xcellsyz Ltd.* (UK) |
Boehringer Ingelheim GmbH (Germany) |
BI nonexclusively licensed immortalized human skeletal muscle cell lines |
BI will use the lines for evaluation and drug discovery research; terms were not disclosed (6/7) |
Zeptosens AG* (Switzerland) |
GlaxoSmithKline plc(UK) |
Deal allowing GSK to have protein microarrays developed for applications in drug discovery and development |
GSK previously acquired the complete platform of Zeptosens' ZeptoMARK Protein Profiling System; terms were not disclosed (4/26) |
ZymoGenetics Inc. (ZGEN) |
Novo Nordisk A/S (Denmark) |
Novo exercised rights under an existing deal to exclusively license a limited number of proteins outside North America |
ZymoGenetics will get $15M over the two- year extension, and would get up-front fees and potential milestones and royalties upon selection of a protein (6/9) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | |||
